Foundation Medicine and EORTC collaborate for SPECTA

European Organisation for Research and Treatment of Cancer (EORTC) and Foundation Medicine collaborate to ascertain eligibility of patients for oncology clinical Trials of  Foundation Medicine’s comprehensive genomic profiling (CGP) tests through he EORTC’s Screening Patients for Efficient Clinical Trial Access (SPECTA) program. Screening Patients for Efficient Clinical Trial Access (SPECTA) program is a pan-European network built by the EORTC with key institutions collaborating to provide efficient access for patients to molecularly driven clinical trials.

Vincent Miller, M.D., chief medical officer at Foundation Medicine said “The EORTC is a renowned leader in integrated translational research, and their SPECTA program is an exciting opportunity for oncologists to utilize our robust genomic profiling tests to more efficiently match patients with appropriate clinical trials. Together, Foundation Medicine and the EORTC can work toward improved access to innovative clinical trials, helping to accelerate precision oncology for more patients.”

The collaboration brings together the EORTC, an independent, non-profit clinical research organization in cancer, and Foundation Medicine, a leader in molecular information that offers a suite of CGP assays that identifies the molecular alterations in an individual’s cancer to inform precision medicine treatment approaches.

As per the terms of the agreement, Foundation Medicine to offer genomic testing services for the SPECTRA program through three of its genomic profiling assays namely  FoundationOne and FoundationACT.